Bicycle Therapeutics plc (BCYC) — Financial statements
Income statement, balance sheet, and cash flow for Bicycle Therapeutics plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 73↑105.8% | 35↑30.8% | 27↑86.5% | 14↑23.6% | 12 | |
| Cost of Revenue | 0.00↓100.0% | 173↑10.5% | 156 | 0.00 | 0.00 | |
| Gross Profit | 73↑152.7% | -138↓6.3% | -130↓995.5% | 14↑23.6% | 12 | |
| Operating Expenses | ||||||
| R&D Expenses | 240↑38.9% | 173↑10.5% | 156↑91.8% | 82↑81.8% | 45 | |
| General & Administrative Expenses | 80↑12.0% | 71↑19.4% | 60↑20.9% | 50↑52.6% | 32 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 80↑12.0% | 71↑19.4% | 60↑20.9% | 50↑52.6% | 32 | |
| Other Expenses | 0.00↑100.0% | -172↓10.5% | -156 | 0.00 | 0.00 | |
| Operating Expenses | 320↑343.8% | 72↑19.5% | 60↓53.9% | 131↑69.6% | 77 | |
| Total Costs & Expenses | 320↑30.7% | 245↑13.0% | 217↑65.4% | 131↑69.6% | 77 | |
| Operating Results | ||||||
| Operating Income | -248↓18.0% | -210↓10.5% | -190↓62.8% | -117↓77.8% | -66 | |
| Depreciation & Amortization | 6↓10.5% | 7↑9.6% | 7↑77.4% | 4↑161.8% | 1 | |
| EBITDA | -212↓28.7% | -165↑10.1% | -183↓71.1% | -107↓67.3% | -64 | |
| EBIT | -219↓27.0% | -172↑9.4% | -190↓71.3% | -111↓69.3% | -65 | |
| Interest & Other Income | ||||||
| Net Interest Income | 28↓13.2% | 33↑203.1% | 11↑345.2% | 2↑184.2% | -3 | |
| Interest Income | 28↓17.0% | 34↑144.9% | 14↑143.3% | 6↑4696.7% | 0.12 | |
| Interest Expense | 0.21↓88.1% | 2↓47.0% | 3↓2.4% | 3↑12.1% | 3 | |
| Non-Operating Income | -29↑23.0% | -38 | 0.00↑100.0% | -6↓4696.7% | -0.12 | |
| Other Income / Expenses | 29↓19.9% | 36↑235.9% | 11↑345.2% | 2↑184.2% | -3 | |
| Income Before Tax | -219↓25.9% | -174↑3.0% | -179↓56.9% | -114↓66.8% | -68 | |
| Income Tax Expense | 0.15↑103.2% | -5↓427.0% | 1↑195.6% | -2↑8.4% | -2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -219↓29.5% | -169↑6.4% | -181↓60.3% | -113↓68.7% | -67 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -219↓29.5% | -169↑6.4% | -181↓60.3% | -113↓68.7% | -67 | |
| Bottom-Line Net Income | -219↓29.5% | -169↑6.4% | -181↓60.3% | -113↓68.7% | -67 | |
| EPS (Basic) | -3.16↓8.6% | -2.91↑42.7% | -5.08↓33.7% | -3.80↓42.3% | -2.67 | |
| EPS (Diluted) | -3.16↓9.0% | -2.90↑42.9% | -5.08↓33.7% | -3.80↓42.3% | -2.67 | |
| Weighted Average Shares | 69↑19.0% | 58↑63.5% | 36↑20.0% | 30↑18.4% | 25 | |
| Weighted Average Diluted Shares | 69↑19.0% | 58↑63.5% | 36↑20.0% | 30↑18.4% | 25 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.